<DOC>
	<DOCNO>NCT01456481</DOCNO>
	<brief_summary>About 20 % adult faint recurrently . These patient often highly symptomatic , problem employment drive reduce quality life . There therapy withstand test adequately design conduct randomized clinical trial . Midodrine prodrug whose metabolite alpha-1 adrenergic agonist increase venous return heart raise blood pressure . There considerable low level evidence might prevent vasovagal syncope . The investigator test hypothesis Midodrine prevents recurrence syncope patient moderate severe vasovagal syncope .</brief_summary>
	<brief_title>Assessment Midodrine Prevention Vasovagal Syncope : The Prevention Syncope Trial IV</brief_title>
	<detailed_description />
	<mesh_term>Syncope</mesh_term>
	<mesh_term>Syncope , Vasovagal</mesh_term>
	<mesh_term>Midodrine</mesh_term>
	<criteria>Patients eligible : ≥2 syncopal spell year precede enrolment , ≥ 2 point Syncope Symptom Score Structurally Normal heart , Age ≥ 18 year informed consent . Patients exclude : cause syncope , ventricular tachycardia , complete heart block , postural hypotension hypersensitive carotid sinus syndrome , inability give inform consent , important valvular , coronary , myocardial conduction abnormality significant arrhythmia , hypertrophic cardiomyopathy , permanent pacemaker , seizure disorder , urinary retention , hypertension define &gt; 140/90 mm Hg , hepatic disease , glaucoma 5minute stand test result diagnosis Postural Orthostatic Tachycardia Syndrome Orthostatic Hypotension .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>reflex fainting</keyword>
	<keyword>vasovagal syncope</keyword>
	<keyword>midodrine</keyword>
</DOC>